Healthcare Tips

Without Preventative Treatment, Over 400 People May Die From Hospital-acquired Blood Clots This National Thrombosis Week

September 22, 2017

Head-to-head data published today shows new, Xarelto® (rivaroxaban) is the only oral anticoagulant to significantly reduce the incidence of potentially deadly blood clots when compared with the current standard of care, enoxaparin, in adults undergoing elective hip or knee replacement surgery. Data published today in The Journal of Bone and Joint Surgery show that oral Xarelto is significantly more effective at reducing the incidence of the composite of symptom-causing blood clots, known as venous thromboembolism (VTE), and death, than injectable enoxaparin following elective orthopaedic surgery. These findings make Xarelto the only oral anticoagulant to significantly reduce clinically relevant blood clots when compared with the current standard of care.2

With publication of these data marking the start of National Thrombosis Week (11 - 15th May), Professor Beverley Hunt, Consultant Haematologist and Medical Director of Lifeblood: The Thrombosis Charity, comments: "hospital-acquired blood clots are the leading cause of preventable death, killing hundreds of people every week. Lifeblood support Thrombosis Awareness Week as a means of highlighting the need for suitable preventative treatment for every adult admitted to hospital. We welcome rivaroxaban which in clinical trials, has been proven to be superior to the gold standard after major orthopaedic surgery and has the advantage of being an easy-to-take tablet."

The pooled analysis of three pivotal Phase III trials, RECORD1, 2 & 3, involved 9,581 patients and showed that two weeks therapy with Xarelto (10 mg tablet, once-daily) provided patients with a 56% relative risk reduction in the incidence of the composite of symptom-causing VTE and death from all causes, when compared to two weeks therapy with enoxaparin (40 mg injection, once-daily) (0.4% versus 0.8% respectively, p The primary endpoint for the pooled RECORD1-3 analysis was symptomatic VTE - defined as symptomatic deep vein thrombosis (DVT) and symptomatic non-fatal pulmonary embolism - and all-cause mortality, measured within a 12-day treatment phase to incorporate the enoxaparin-controlled period across all three studies and allow for an unbiased comparison.2 Data also showed that patients treated with Xarelto experienced significant reductions in the incidence of the composite of symptomatic VTE and all-cause mortality at the end of the planned medication period (p